Description
Glukagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor. Appearance:SolidIC50& Target:GLP-1 receptor. In Vitro:Glukagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proGlukagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4hIn Vivo:GLP-1(1–37) decreases glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group. MCE has not independently confirmed the accuraBiological Activity:Glukagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor